Article
Oncology
Yasuhiro Nagata, Shinichi Kageyama, Takeshi Ishikawa, Satoshi Kokura, Tetsuya Okayama, Tetsuya Abe, Masahiko Murakami, Koji Otsuka, Tomotake Ariyoshi, Takashi Kojima, Ken Taniguchi, Shinichiro Kobayashi, Hideaki Shimada, Satoshi Yajima, Takashi Suzuki, Satoshi Hirano, Takahiro Tsuchikawa, Toshiaki Shichinohe, Shugo Ueda, Kengo Kanetaka, Akira Yoneda, Hisashi Wada, Yuichiro Doki, Hiroki Yamaue, Masahiro Katsuda, Masaki Ohi, Hiromi Yasuda, Ken Kondo, Masato Kataoka, Yasuhiro Kodera, Masahiko Koike, Taizo Shiraishi, Yoshihiro Miyahara, Naoki Goshima, Eriko Fukuda, Kei Yamaguchi, Eiichi Sato, Hiroaki Ikeda, Tomomi Yamada, Masaharu Osako, Kaoru Hirai, Hiroshi Miyamoto, Takashi Watanabe, Hiroshi Shiku
Summary: The study aimed to determine the efficacy and biomarkers of the CHP-NY-ESO-1 vaccine in ESCC patients, revealing the vaccine's safety and potential prognostic factors.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Immunology
Hong Zhou, Yipeng Ma, Fenglan Liu, Bin Li, Dongjuan Qiao, Peigen Ren, Mingjun Wang
Summary: NY-ESO-1 is a highly immunogenic tumor-associated antigen that is widely used in cancer immunotherapy. There are various types of NY-ESO-1-based cancer vaccines, each with its own advantages and obstacles, but they are of great significance for the treatment of solid cancers.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Takeshi Ishikawa, Shinichi Kageyama, Yoshihiro Miyahara, Tetsuya Okayama, Satoshi Kokura, Linan Wang, Eiichi Sato, Hideo Yagita, Yoshito Itoh, Hiroshi Shiku
Summary: The vaccine combining CHP-NY-ESO-1 and poly-ICLC showed good safety and immune response in a phase 1 clinical trial, with no observed tumor responses. All patients achieved antibody responses, with higher titers in the combination group.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Sandra N. Freiberger, David Holzmann, Gregoire B. Morand, Martin Huellner, Mitchell P. Levesque, Reinhard Dummer, Viktor H. Koelzer, Niels J. Rupp
Summary: This study investigates novel biomarkers in mucosal melanoma that predict response to combined ipilimumab and nivolumab immunotherapy. The results suggest that the testis antigens CTAG1B (NY-ESO-1), MAGE-A3, and MAGE-A4 are predominantly expressed in responding tumors, and could potentially be used for future routine diagnostics to predict treatment outcomes.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medical Laboratory Technology
Yumiko Sakai, Koji Kurose, Kanako Sakaeda, Hirotaka Abo, Yusuke Atarashi, Nobuyuki Ide, Toshiyuki Sato, Eiichiro Kanda, Minoru Fukuda, Toru Oga, Kenta Noda, Mikio Oka
Summary: The study developed a fully automated immunoassay system to measure NY-ESO-1/XAGE1 antibody levels in NSCLC patients. Results showed that levels of NY-ESO-1/XAGE1 antibodies were significantly higher in NSCLC patients who responded to anti-PD-1 monotherapy compared to non-responders and healthy donors. The combination prediction with NY-ESO-1/XAGE1 antibodies achieved the highest AUROC value.
CLINICA CHIMICA ACTA
(2021)
Article
Pathology
Max Julve, Oliver Kennedy, Adam Enver Frampton, Izhar Bagwan, Mark P. Lythgoe
Summary: CTAG1B/NY-ESO-1, as a member of the cancer testis antigen family, holds promising potential in cancer immunotherapy. This article discusses the structure, function, and immunohistochemical detection of CTAG1B/NY-ESO-1, as well as the latest advances in associated anti-cancer therapies.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Medicine, General & Internal
Kazuhiko Hashimoto, Shunji Nishimura, Yu Shinyashiki, Tomohiko Ito, Ryosuke Kakinoki, Masao Akagi
Summary: This study aimed to determine the involvement of NY-ESO-1 and MAGE-A4 in desmoid tumors (DTs) and found that both might be involved in the DT microenvironment, suggesting that they may serve as diagnostic markers for DTs.
Article
Biochemistry & Molecular Biology
Synat Kang, Lixin Wang, Lu Xu, Ruiqi Wang, Qingzheng Kang, Xuefeng Gao, Li Yu
Summary: Research shows that the combined use of NY-ESO-1-specific dTCR-T cells and DAC can effectively suppress the growth of leukemia cells and prolong the survival of AML patients.
Article
Multidisciplinary Sciences
Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, E. Andres Houseman, Shan Zhong, Jaegil Kim, Michael Nathenson, Thomas Faitg, Mary Woessner, David C. Turner, Aisha N. Hasan, John Glod, Rosandra N. Kaplan, Sandra P. D'Angelo, Dejka M. Araujo, Warren A. Chow, Mihaela Druta, George D. Demetri, Brian A. Van Tine, Stephan A. Grupp, Gregg D. Fine, Ioanna Eleftheriadou
Summary: This study identifies potential predictive and pharmacodynamic markers of response to NY-ESO-1 T-cell therapy in a solid tumor, which may inform lymphodepletion, cell dose, and strategies to enhance anticancer efficacy.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Sant P. Chawla, Brian A. Van Tine, Seth M. Pollack, Kristen N. Ganjoo, Anthony D. Elias, Richard F. Riedel, Steven Attia, Edwin Choy, Scott H. Okuno, Mark Agulnik, Margaret von Mehren, Michael B. Livingston, Vicki L. Keedy, Claire F. Verschraegen, Tony Philip, G. Chet Bohac, Sergey Yurasov, Adam Yakovich, Hailing Lu, Michael Chen, Robert G. Maki
Summary: This study investigated the efficacy and safety of combining the CMB305 regimen with atezolizumab compared to atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma. The combination therapy resulted in improved NY-ESO-1-specific T-cell and antibody responses, but did not significantly increase progression-free survival or overall survival compared to atezolizumab alone.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Naohiro Oka, Ryosuke Kakinoki, Masao Akagi
Summary: The study aimed to investigate the clinical significance of NY-ESO-1 and MAGE-A4 in osteosarcoma, suggesting that these antigens may be involved in the aggressiveness of OS. However, there was no significant difference in the expression rates of NY-ESO-1 or MAGE-A4 between different patient groups.
EUROPEAN JOURNAL OF HISTOCHEMISTRY
(2022)
Article
Cell Biology
Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Naohiro Oka, Ryosuke Kakinoki, Masao Akagi
Summary: This study aims to investigate the clinical significance of NY-ESO-1 and MAGE-A4 in osteosarcoma (OS). The results suggest that NY-ESO-1 and MAGE-A4 may be involved in the aggressiveness of OS.
EUROPEAN JOURNAL OF HISTOCHEMISTRY
(2022)
Article
Oncology
Craig L. Slingluff, Hassane M. Zarour, Hussein Abdul-Hassan Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander, Craig E. Devoe, Elizabeth M. Gaughan, Ileana S. Mauldin, Walter C. Olson, Kelly T. Smith, Mary J. Macri, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok
Summary: Treatment with IPI + NY-ESO-1 vaccines enhanced T cell and antibody responses in patients. Patients with best clinical responses had broader antibody responses and increased T cell densities.
Article
Oncology
Mikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, Yoshihiro Miyahara, Noboru Yamamoto, Hidefumi Kato, Hideyuki Mishima, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Tetsuro Sasada, Eiichi Sato, Sachiko Okamoto, Daisuke Tomura, Ikuei Nukaya, Hideto Chono, Junichi Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, Hiroaki Ikeda, Takashi Watanabe, Hiroshi Shiku
Summary: This study investigated the use of T-cell receptor (TCR)-engineered T cells to treat patients with solid tumors expressing NY-ESO-1. The results showed significant tumor response and some patients experienced early-onset cytokine release syndrome (CRS). One patient developed severe lung injury associated with the TCR-T cell infusion.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Luke Frankiw, Arun Singh, Cole Peters, Begona Comin-Anduix, Beata Berent-Maoz, Mignonette Macabali, Kiana Shammaie, Crystal Quiros, Paula Kaplan-Lefko, Ignacio Baselga Carretero, Antoni Ribas, Theodore Scott Nowicki
Summary: In this study, a new mechanism of treatment resistance in sarcoma involving loss of NY-ESO-1 expression after transgenic adoptive cell therapy with dendritic cell vaccination and PD-1 blockade was described. Initial tumor regression was observed, but tumor progression and loss of NY-ESO-1 expression were found later. This study provides insights for improving cellular therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Helen X. Chen, Minkyung Song, Holden T. Maecker, Sacha Gnjatic, David Patton, J. Jack Lee, Stacey J. Adam, Radim Moravec, Xiaole Shirley Liu, Ethan Cerami, James Lindsay, Ming Tang, F. Stephen Hodi, Catherine J. Wu, Ignacio I. Wistuba, Gheath Al-Atrash, Chantale Bernatchez, Sean C. Bendall, Stephen M. Hewitt, Elad Sharon, Howard Streicher, Rebecca A. Enos, Melissa D. Bowman, Valerie M. Tatard-Leitman, Beatriz Sanchez-Espiridion, Srinika Ranasinghe, Mina Pichavant, Diane M. Del Valle, Joyce Yu, Sylvie Janssens, Jenny Peterson-Klaus, Cathy Rowe, Gerold Bongers, Robert R. Jenq, Chia-Chi Chang, Jeffrey S. Abrams, Margaret Mooney, James H. Doroshow, Lyndsay N. Harris, Magdalena Thurin
Summary: Immunoprofiling for identifying biomarkers and integrating with clinical trial outcomes play a critical role in improving immunotherapy for cancer patients. The CIMAC-CIDC Network aims to establish an infrastructure for systematic biomarker identification and correlation with clinical outcomes across trials, facilitated by harmonized assays and computational expertise. By establishing this network, immuno-oncology biomarker development and cross-trial data analysis can be enhanced.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemical Research Methods
Daniel Geanon, Brian Lee, Edgar Gonzalez-Kozlova, Geoffrey Kelly, Diana Handler, Bhaskar Upadhyaya, John Leech, Ronaldo M. De Real, Manon Herbinet, Assaf Magen, Diane Del Valle, Alexander Charney, Seunghee Kim-Schulze, Sacha Gnjatic, Miriam Merad, Adeeb H. Rahman
Summary: Mass cytometry is a powerful tool for immune phenotyping, but its wide deployment is hindered by complex workflows and specialized equipment requirements. The streamlined workflow presented in this study, using commercially available reagents, addresses these challenges and enables broader adoption of CyTOF immune monitoring. The workflow allows for easy staining of whole blood samples on site, followed by batch processing at a central facility, showcasing disease-related changes in immune cells.
Article
Oncology
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Marino-Enriquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, Stephen F. Hodi, Jonathan D. Schoenfeld
Summary: This study demonstrated the feasibility and safety of adding low-dose fractionated radiation (LDFRT) and hypofractionated radiation (HFRT) to PD-L1/CTLA-4 blockade in patients with metastatic colorectal cancer. While the primary endpoint showed stable disease, biomarkers supported the impact of both LDFRT and HFRT on the immune microenvironment and immunogenicity.
CLINICAL CANCER RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Alexandra E. Livanos, Divya Jha, Francesca Cossarini, Ana S. Gonzalez-Reiche, Minami Tokuyama, Teresa Aydillo, Tommaso L. Parigi, Mark S. Ladinsky, Irene Ramos, Katie Dunleavy, Brian Lee, Rebekah E. Dixon, Steven T. Chen, Gustavo Martinez-Delgado, Satish Nagula, Emily A. Bruce, Huaibin M. Ko, Benjamin S. Glicksberg, Girish Nadkarni, Elisabet Pujadas, Jason Reidy, Steven Naymagon, Ari Grinspan, Jawad Ahmad, Michael Tankelevich, Yaron Bram, Ronald Gordon, Keshav Sharma, Jane Houldsworth, Graham J. Britton, Alice Chen-Liaw, Matthew P. Spindler, Tamar Plitt, Pei Wang, Andrea Cerutti, Jeremiah J. Faith, Jean-Frederic Colombel, Ephraim Kenigsberg, Carmen Argmann, Miriam Merad, Sacha Gnjatic, Noam Harpaz, Silvio Danese, Carlos Cordon-Cardo, Adeeb Rahman, Robert E. Schwartz, Nikhil A. Kumta, Alessio Aghemo, Pamela J. Bjorkman, Francesca Petralia, Harm van Bakel, Adolfo Garcia-Sastre, Saurabh Mehandru
Summary: This study found that although SARS-CoV-2 was detected in the gastrointestinal tract, there was no inflammatory response in the intestine. Additionally, COVID-19 patients with gastrointestinal symptoms had reduced disease severity and mortality.
Correction
Biochemistry & Molecular Biology
Alexander W. Charney, Nicole W. Simons, Konstantinos Mouskas, Lauren Lepow, Esther Cheng, Jessica Le Berichel, Christie Chang, Robert Marvin, Diane Marie Del Valle, Sharlene Calorossi, Alona Lansky, Laura Walker, Manishkumar Patel, Hui Xie, Nancy Yi, Alex Yu, Gurpawan Kang, Lora E. Liharska, Emily Moya, Matthew Hartnett, Sandra Hatem, Lillian Wilkins, Melody Eaton, Hajra Jamal, Kevin Tuballes, Steven T. Chen, Alexandra Tabachnikova, Jonathan Chung, Jocelyn Harris, Craig Batchelor, Jose Lacunza, Mahlet Yishak, Kimberly Argueta, Neha Karekar, Brian Lee, Geoffrey Kelly, Daniel Geanon, Diana Handler, John Leech, Hiyab Stefanos, Travis Dawson, Ieisha Scott, Nancy Francoeur, Jessica S. Johnson, Akhil Vaid, Benjamin S. Glicksberg, Girish N. Nadkarni, Eric E. Schadt, Bruce D. Gelb, Adeeb Rahman, Robert Sebra, Glenn Martin, Charuta Agashe, Charuta Agashe, Priyal Agrawal, Kasey Alesso-Carra, Eziwoma Alibo, Kelvin Alvarez, Angelo Amabile, Steven Ascolillo, Rasheed Bailey, Priya Begani, Paloma Bravo Correra, Stacey-Ann Brown, Mark Buckup, Larissa Burka, Lena Cambron, Gina Carrara, Serena Chang, Jonathan Chien, Mashkura Chowdhury, Cansu Cimen Bozkus, Phillip Comella, Dana Cosgrove, Francesca Cossarini, Liam Cotter, Arpit Dave, Bheesham Dayal, Maxime Dhainaut, Rebecca Dornfeld, Katie Dul, Nissan Eber, Cordelia Elaiho, Frank Fabris, Jeremiah Faith, Dominique Falci, Susie Feng, Brian Fennessy, Marie Fernandes, Sandeep Gangadharan, Joanna Grabowska, Gavin Gyimesi, Maha Hamdani, Manon Herbinet, Elva Herrera, Arielle Hochman, Gabriel E. Hoffman, Jaime Hook, Laila Horta, Etienne Humblin, Subha Karim, Jessica Kim, Dannielle Lebovitch, Grace Lee, Gyu Ho Lee, Jacky Lee, Mike Leventhal, Katherine Lindblad, Alexandra Livanos, Rosalie Machado, Zafar Mahmood, Kelcey Mar, Shrisha Maskey, Paul Matthews, Katherine Meckel, Saurabh Mehandru, Cynthia Mercedes, Dara Meyer, Gurkan Mollaoglu, Sarah Morris, Kai Nie, Marjorie Nisenholtz, George Ofori-Amanfo, Kenan Onel, Merouane Ounadjela, Vishwendra Patel, Cassandra Pruitt, Shivani Rathi, Jamie Redes, Ivan Reyes-Torres, Alcina Rodrigues, Alfonso Rodriguez, Vladimir Roudko, Evelyn Ruiz, Pearl Scalzo, Pedro Silva, Alessandra Soares Schanoski, Meghan Straw, Sasha Tabachnikova, Collin Teague, Bhaskar Upadhyaya, Verena van der Heide, Natalie Vaninov, Daniel Wacker, Hadley Walsh, C. Matthias Wilk, Jessica Wilson, Karen M. Wilson, Li Xue, Naa-akomaah Yeboah, Sabina Young, Nina Zaks, Renyuan Zha, Thomas Marron, Noam Beckmann, Seunghee Kim-Schulze, Sacha Gnjatic, Miriam Merad
Article
Oncology
Bita Sahaf, Mina Pichavant, Brian H. Lee, Caroline Duault, Emily M. Thrash, Melanie Davila, Nicolas Fernandez, Karen Millerchip, Salah-Eddine Bentebibel, Cara Haymaker, Natalia Sigal, Diane M. Del Valle, Srinika Ranasinghe, Sarah Fayle, Beatriz Sanchez-Espiridion, Jiexin Zhang, Chantale Bernatchez, Catherine J. Wu, Ignacio I. Wistuba, Seunghee Kim-Schulze, Sacha Gnjatic, Sean C. Bendall, Minkyung Song, Magdalena Thurin, J. Jack Lee, Holden T. Maecker, Adeeb Rahman
Summary: The study aimed to identify biomarkers of response to cancer immunotherapies across clinical trials using state-of-the-art assays and conducted cross-site data harmonization efforts. Results show the ability to reproduce CyTOF data across sites in multicenter trials and emphasize the importance of quality control procedures.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Noam D. Beckmann, Phillip H. Comella, Esther Cheng, Lauren Lepow, Aviva G. Beckmann, Scott R. Tyler, Konstantinos Mouskas, Nicole W. Simons, Gabriel E. Hoffman, Nancy J. Francoeur, Diane Marie Del Valle, Gurpawan Kang, Anh Do, Emily Moya, Lillian Wilkins, Jessica Le Berichel, Christie Chang, Robert Marvin, Sharlene Calorossi, Alona Lansky, Laura Walker, Nancy Yi, Alex Yu, Jonathan Chung, Matthew Hartnett, Melody Eaton, Sandra Hatem, Hajra Jamal, Alara Akyatan, Alexandra Tabachnikova, Lora E. Liharska, Liam Cotter, Brian Fennessy, Akhil Vaid, Guillermo Barturen, Hardik Shah, Ying-chih Wang, Shwetha Hara Sridhar, Juan Soto, Swaroop Bose, Kent Madrid, Ethan Ellis, Elyze Merzier, Konstantinos Vlachos, Nataly Fishman, Manying Tin, Melissa Smith, Hui Xie, Manishkumar Patel, Kai Nie, Kimberly Argueta, Jocelyn Harris, Neha Karekar, Craig Batchelor, Jose Lacunza, Mahlet Yishak, Kevin Tuballes, Ieisha Scott, Arvind Kumar, Suraj Jaladanki, Charuta Agashe, Ryan Thompson, Evan Clark, Bojan Losic, Lauren Peters, Panagiotis Roussos, Jun Zhu, Wenhui Wang, Andrew Kasarskis, Benjamin S. Glicksberg, Girish Nadkarni, Dusan Bogunovic, Cordelia Elaiho, Sandeep Gangadharan, George Ofori-Amanfo, Kasey Alesso-Carra, Kenan Onel, Karen M. Wilson, Carmen Argmann, Supinda Bunyavanich, Marta E. Alarcon-Riquelme, Thomas U. Marron, Adeeb Rahman, Seunghee Kim-Schulze, Sacha Gnjatic, Bruce D. Gelb, Miriam Merad, Robert Sebra, Eric E. Schadt, Alexander W. Charney
Summary: Multisystem inflammatory syndrome in children (MIS-C) presents symptoms similar to Kawasaki disease and affects individuals under 21 years of age. RNA sequencing revealed signatures related to natural killer cell activation and CD8+ T cell exhaustion in the blood of MIS-C patients, showing similarities with Kawasaki disease.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Sapna P. Patel, Gina R. Petroni, Jason Roszik, Walter C. Olson, Nolan A. Wages, Kimberly A. Chianese-Bullock, Mark Smolkin, Nikole Varhegyi, Elizabeth Gaughan, Kelly T. Smith, Kathleen Haden, Emily H. Hall, Sacha Gnjatic, Patrick Hwu, Craig L. Slingluff
Summary: This study evaluated the safety and immunogenicity of a novel long peptide vaccine with different adjuvants, showing that the LPV7 vaccine induced certain immune responses under various adjuvant strategies, but did not significantly enhance T cell responses compared to vaccines using short peptides.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Mary Zhang, Julie A. Hong, Tricia F. Kunst, Colleen D. Bond, Cara M. Kenney, Cheryl L. Warga, Javier Yeray, Min-Jung Lee, Akira Yuno, Sunmin Lee, Markku Miettinen, R. Taylor Ripley, Chuong D. Hoang, Sacha Gnjatic, Jane B. Trepel, David S. Schrump
Summary: This study demonstrates that H1299 lysate vaccines with Iscomatrix™ can induce immune responses to CTA and decrease the percentage of Treg cells while modulating the expression of immune-related molecules on other cells. However, metronomic cyclophosphamide and celecoxib did not enhance the vaccine-induced immune responses.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Mami Oikawa, Mayuko Nagae, Naoaki Mizuno, Kenyu Iwatsuki, Fumika Yoshida, Naoko Inoue, Yoshihisa Uenoyama, Hiroko Tsukamura, Hiromitsu Nakauchi, Masumi Hirabayashi, Toshihiro Kobayashi
Summary: In this study, various gene targeting strategies were compared to generate a novel knock-in reporter rat line. By visualizing the expression pattern of the transcription factor Tfap2c, this rat line can be used to identify and purify cells expressing Tfap2c in rats, making it a valuable resource.
MOLECULAR REPRODUCTION AND DEVELOPMENT
(2022)
Article
Multidisciplinary Sciences
Mami Oikawa, Hisato Kobayashi, Makoto Sanbo, Naoaki Mizuno, Kenyu Iwatsuki, Tomoya Takashima, Keiko Yamauchi, Fumika Yoshida, Takuya Yamamoto, Takashi Shinohara, Hiromitsu Nakauchi, Kazuki Kurimoto, Masumi Hirabayashi, Toshihiro Kobayashi
Summary: The in vitro generation of germ cells from pluripotent stem cells has significant implications for reproductive medicine and animal breeding. In this study, researchers successfully induced functional primordial germ cell-like cells from rat pluripotent stem cells and generated functional spermatids through transplantation. This research provides insights into the mechanisms of in vitro gametogenesis and has implications for broader applications.
Article
Multidisciplinary Sciences
Kazuto Yamazaki, Kenji Kubara, Satoko Ishii, Peng Li, Ryo Dairiki, Taro Hihara, Yuta Ishizuka, Yukina Izumi, Minoru Kumai, Tsutomu Kamisako, Hiroyoshi Ishizaki, Hideyuki Sato, Hideki Masaki, Naoaki Mizuno, Kaoru Mitsuhashi, Masashi Ito, Sanae Hamanaka, Tomoyuki Yamaguchi, Motoo Watanabe, Fumihiro Sugiyama, Hiromitsu Nakauchi
Summary: The study demonstrates the successful generation of thymus-complemented chimeric mice through blastocyst complementation, confirming the functionality of the complemented organs and cells in the chimeric animals. The findings have implications for regenerative medicine and drug development.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Myvizhi Esai Selvan, Kenan Onel, Sacha Gnjatic, Robert J. Klein, Zeynep H. Gumus
Summary: Recent studies have shown that rare, deleterious variants (RDVs) in specific genes play a critical role in heritable cancer risk. By analyzing whole-exome sequencing data of 20,789 participants, we identified associations between cancer risk and RDVs in DNA repair, cancer predisposition, and somatic cancer drivers. Moreover, we found that personal RDV load in these gene-sets is associated with increased risk, earlier onset, increased M1 macrophages in tumor, and increased tumor mutational burden in specific cancers. These findings can be used to identify high-risk individuals and improve prognosis through increased surveillance, earlier screening, and targeted treatments.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
Beryl L. Manning-Geist, Sacha Gnjatic, Carol Aghajanian, Jason Konner, Sarah H. Kim, Debra Sarasohn, Krysten Soldan, William P. Tew, Nicholas J. Sarlis, Dmitriy Zamarin, Sara Kravetz, Ilaria Laface, Teresa Rasalan-Ho, Jingjing Qi, Phillip Wong, Paul J. Sabbatini, Roisin E. O'Cearbhaill
Summary: A combination therapy of WT1 peptide vaccine and nivolumab has been found to induce immune responses in ovarian cancer patients, and it is safe and tolerable. This study provides additional evidence for the combination of immune checkpoint inhibitors and vaccines.
Meeting Abstract
Oncology
Camille Bigenwald, Jessica Le Berichel, Rikhia Chakraborty, Steven T. Chen, Guray Akturk, Alexandra Tabachnikova, Anahita Rafiei, Ilaria Laface, Howard Lim, Alessia Baccarini, Poulikos I. Poulikakos, Brian D. Brown, Sacha Gnjatic, Amaia Lujambio, Markus G. Man, Kenneth L. McClain, Jennifer Picarsic, Carl E. Allen, Miriam Merad
PEDIATRIC BLOOD & CANCER
(2021)
